352 related articles for article (PubMed ID: 32134137)
1. Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer.
Yamada Y; Sakamoto S; Rii J; Yamamoto S; Kamada S; Imamura Y; Nakamura K; Komiya A; Nakatsu H; Ichikawa T
Prostate; 2020 May; 80(7):559-569. PubMed ID: 32134137
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R
Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.
Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151
[TBL] [Abstract][Full Text] [Related]
5. Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma.
Dalpiaz O; Luef T; Seles M; Stotz M; Stojakovic T; Pummer K; Zigeuner R; Hutterer GC; Pichler M
Br J Cancer; 2017 Jan; 116(1):85-90. PubMed ID: 27907929
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory markers as prognostic factors in metastatic castration-resistant prostate cancer.
Donate-Moreno MJ; Lorenzo-Sánchez MV; Díaz de Mera-Sánchez Migallón I; Herraiz-Raya L; Esper-Rueda JA; Legido-Gómez O; Rico-Marco S; Salinas-Sánchez AS
Actas Urol Esp (Engl Ed); 2020 Dec; 44(10):692-700. PubMed ID: 33010988
[TBL] [Abstract][Full Text] [Related]
7. High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine.
Li L; Ai L; Jia L; Zhang L; Lei B; Zhang Q
BMC Cancer; 2022 Jan; 22(1):29. PubMed ID: 34980025
[TBL] [Abstract][Full Text] [Related]
8. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
[TBL] [Abstract][Full Text] [Related]
9. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.
Lorente D; Mateo J; Templeton AJ; Zafeiriou Z; Bianchini D; Ferraldeschi R; Bahl A; Shen L; Su Z; Sartor O; de Bono JS
Ann Oncol; 2015 Apr; 26(4):750-755. PubMed ID: 25538172
[TBL] [Abstract][Full Text] [Related]
10. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.
Boegemann M; Schlack K; Thomes S; Steinestel J; Rahbar K; Semjonow A; Schrader AJ; Aringer M; Krabbe LM
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208664
[TBL] [Abstract][Full Text] [Related]
11. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio.
Templeton AJ; Pezaro C; Omlin A; McNamara MG; Leibowitz-Amit R; Vera-Badillo FE; Attard G; de Bono JS; Tannock IF; Amir E
Cancer; 2014 Nov; 120(21):3346-52. PubMed ID: 24995769
[TBL] [Abstract][Full Text] [Related]
12. Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer.
Lozano Martínez AJ; Moreno Cano R; Escobar Páramo S; Salguero Aguilar R; Gonzalez Billalabeitia E; García Fernández R; De La Fuente Muñoz I; Romero Borque A; Porras Martínez M; Lopez Soler F; Cardenas Cánovas E; Ortega Martín I
Clin Transl Oncol; 2017 Dec; 19(12):1531-1536. PubMed ID: 28718070
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients.
Hu H; Yao X; Xie X; Wu X; Zheng C; Xia W; Ma S
World J Urol; 2017 Feb; 35(2):261-270. PubMed ID: 27255479
[TBL] [Abstract][Full Text] [Related]
14. Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.
Chong W; Zhang Z; Luo R; Gu J; Lin J; Wei Q; Li B; Myers R; Lu-Yao G; Kelly WK; Wang C; Yang H
BMC Cancer; 2021 Jun; 21(1):655. PubMed ID: 34078304
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study.
Takada K; Takamori S; Matsubara T; Haratake N; Akamine T; Kinoshita F; Ono Y; Wakasu S; Tanaka K; Oku Y; Oba T; Osoegawa A; Tagawa T; Takenoyama M; Shimokawa M; Oda Y; Mori M
PLoS One; 2020; 15(11):e0241580. PubMed ID: 33137158
[TBL] [Abstract][Full Text] [Related]
16. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients.
Absenger G; Szkandera J; Pichler M; Stotz M; Arminger F; Weissmueller M; Schaberl-Moser R; Samonigg H; Stojakovic T; Gerger A
Br J Cancer; 2013 Jul; 109(2):395-400. PubMed ID: 23820252
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617.
Şahin E; Kefeli U; Zorlu Ş; Seyyar M; Ozkorkmaz Akdag M; Can Sanci P; Karakayali A; Ucuncu Kefeli A; Bakkal Temi Y; Cabuk D; Uygun K
Medicine (Baltimore); 2023 Nov; 102(47):e35843. PubMed ID: 38013293
[TBL] [Abstract][Full Text] [Related]
18. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.
Nuhn P; Vaghasia AM; Goyal J; Zhou XC; Carducci MA; Eisenberger MA; Antonarakis ES
BJU Int; 2014 Dec; 114(6b):E11-E17. PubMed ID: 24529213
[TBL] [Abstract][Full Text] [Related]
19. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.
Ferrucci PF; Ascierto PA; Pigozzo J; Del Vecchio M; Maio M; Antonini Cappellini GC; Guidoboni M; Queirolo P; Savoia P; Mandalà M; Simeone E; Valpione S; Altomonte M; Spagnolo F; Cocorocchio E; Gandini S; Giannarelli D; Martinoli C
Ann Oncol; 2016 Apr; 27(4):732-8. PubMed ID: 26802161
[TBL] [Abstract][Full Text] [Related]
20. Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases.
Neal CP; Cairns V; Jones MJ; Masood MM; Nana GR; Mann CD; Garcea G; Dennison AR
Med Oncol; 2015 May; 32(5):144. PubMed ID: 25807934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]